turning to results, third quarter total company sales of $num-one billion increased num-two% on a constant-currency basis versus the year-ago period. we continue to expect our full-year rate in year-six, excluding special items to be between num-three% and num-four%, including an estimated benefit of four percentage points from stock-based compensation accounting.
earnings in the quarter of $num-one met our expectations as covid -related constrained spending more than offset lower-than-expected sales.
globally, our average selling price remained stable.
we continue to expect our full-year rate in year-six, excluding special items to be between num-one% and num-two%, including an estimated benefit of four percentage points from stock-based compensation accounting.
our tavr sales in july benefited from encouraging signs of continued recovery from the pandemic, however procedures were negatively impacted in the last two months of qtr-three due to the significant impact delta had on hospital resources.